FDA will drop two-study requirement for new drug approvals, aiming to speed access
WASHINGTON (AP) — The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous…
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Doctors Warn: Common Daily Supplement Mistake Could Harm Your Health
About 75% of Americans take some kind of supplement regularly, making it a common practice in the U.S.…
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route
Feb 17 (Reuters) – Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for…
Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Over-the-counter ivermectin sales proposed in Georgia
ATLANTA, Ga. (Atlanta News First) — A Georgia state lawmaker wants to allow over-the-counter sales of a drug…
Let’s Be Honest About Public Health Guidance – Emily Oster
In the first week of January, the Health and Human Services Department, under Secretary Robert F. Kennedy Jr.,…
Supplement Recalled Over Potential ‘Life-Threatening’ Side Effects, FDA Reports
The U.S. Food & Drug Administration has recalled a dietary supplement from Modern Warrior. The recall is due…
Supplement Recalled Over Potential ‘Life-Threatening’ Side Effects, FDA Reports
The U.S. Food & Drug Administration has recalled a dietary supplement from Modern Warrior. The recall is due…
Obesity, M&A, Biotech Resurgence: A 2026 Guide to Health Stocks
The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth…
AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)
Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated…
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
WASHINGTON, Jan. 8, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received…